No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia

Clinical Drug Investigation

Volumn 16, Issue 5, 1998, Pages 393-398

  Avenoso, Angela ^a   Facciolà, Gabriella ^a   Scordo, Maria Gabriella ^a   Gitto, Carmelo ^b   Ferrante, Giuseppina Drago ^b   Madia, Aldo G ^b   Spina, Edoardo ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b Azienda USL Messina 5   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0031730419     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816050-00007     Document Type: Article

References (32)

1. Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991; 17: 649-57
2. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind. placebo controlled study. Biol Psychiatry 1992; 31: 698-704
3. Spina E, De Domenico P, Ruello C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994; 9: 281-5
4. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996; 11 Suppl. 5: 31-61
5. Sproule BA, Naranjo CA, Bremner KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 1997; 33: 454-71
6. Bertilsson L, Dahl M-L. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200-23
7. Golf D, Midha K, Brotman A, et al. Elevation of plasma concentrations of haloperidol alter addition of fluoxetine. Am J Psychiatry 1991; 148: 790-2
8. Avenoso A, Spina E, Campo G, et al. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 1997; 35: 335-9
9. Ozdemir V, Naranjo CA, Herrmann N, et al. Paroxetine potentiates CNS side effects of perphenazine: contribution of cytochrome P450 2D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62: 334-47
10. Syvalahti EK, Taiminen T, Saarijarvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997; 25: 24-32
11. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996; 16: 177-87
12. Hiemke C, Weighmann H, Dahmen N, et al. Elevated serum levels of clozapine after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279-81
13. Jerling M, Lindstrom L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-74
14. Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994; 151: 123-5
15. Centorrino F, Baldessarini RJ, Frankenburg F, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153: 820-2
16. Spina E, Avenoso A, Facciolà G, et al. Effect of fluoxetine on plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998; 13: 141-5
17. Taylor D, Ellison Z, Shaw LE, et al. Co-administration of citalopram and clozapine: effect on plasma clozapine levels. Int Clin Psychopharmacol 1998; 13: 19-21
18. Andreasen NC. Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa, 1983
19. Avenoso A, Facciolà G, Campo GM, et al. Determination of clozapine. N-desmethylclozapine, and clozapine N-oxide in human plasma by reverse phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 1998; 714: 299-308
20. Olesen OV, Linnet K. Simplified high-performance liquid Chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Appl 1997; 698: 209-16
21. Oyehaug E, Ostensen ET, Salvesen B. High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr B Biomed Appl 1984; 308: 199-208
22. Andreasen NC. Scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa, 1984
23. Simpson GM, Angus JWS. Drug-induced extrapyramidal disorders. Acta Psychiatr Scand 1970; 212 Suppl.: 11-9
24. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with the CYP1A2 activity determined by the calfeine test. Br J Clin Pharmacol 1994; 38: 471-3
25. Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997; 25: 1379-82
26. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439-44
27. Brosen K, Skielbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-4
28. Rasmussen BB, Maenpaa J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39: 151-9
29. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 activity in human liver. Br J Clin Pharmacol 1992; 34: 262-5
30. Kobayashi K, Yamamoto T, Chiba K, et al. The effects of serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995; 40: 481-5
31. Pies R. Extrapyramidal side effects with low-dose risperidone. Can J Psychiatry 1997; 42: 881
32. Salokongas RK, Saarijarvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94: 175-80